Tisento Therapeutics is a Cambridge, MA-based developer of novel medicines targeting diseases with significant unmet needs. The company launched with an $81m Series A financing to advance its pipeline. Tisento acquired zagociguat and CY3018 from Cyclerion; zagociguat is a Phase 2 soluble guanylate cyclase (sGC) stimulator being developed for MELAS and other genetic mitochondrial diseases, while CY3018 is a CNS-targeted sGC stimulator in IND-enabling studies. The company intends to use the funds to develop zagociguat in MELAS and other genetic mitochondrial diseases and to advance additional assets for serious diseases with unmet need. As part of the asset purchase, Cyclerion received 10% equity ownership in Tisento with anti-dilution protection through a $100m post-money valuation and the right to purchase additional equity, and Cyclerion received a $10.4m cash payment (including an $8m upfront payment and reimbursements). In conjunction with the asset sale, Tisento CEO Peter Hecht invested $5m in Cyclerion.

Total raised

$81M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2023